Cantor Fitzgerald Reiterates "Overweight" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report)'s stock had its "overweight" rating restated by equities research analysts at Cantor Fitzgerald in a note issued to investors on Monday,Benzinga reports. They currently have a $7.00 price target on the stock. Cantor Fitzgerald's price target suggests a potential upside of 277.36% from the stock's current price.

Other equities analysts also recently issued research reports about the stock. Needham & Company LLC reissued a "buy" rating and set a $6.00 price target on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Chardan Capital reissued a "buy" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies currently has an average rating of "Buy" and an average target price of $6.63.

Taysha Gene Therapies Trading Up 5.4 %

NASDAQ TSHA traded up $0.10 during mid-day trading on Monday, hitting $1.86. The company's stock had a trading volume of 177,315 shares, compared to its average volume of 2,701,984. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $4.32. The stock's fifty day simple moving average is $1.55 and its two-hundred day simple moving average is $1.80. The firm has a market capitalization of $380.38 million, a P/E ratio of 2.94 and a beta of 0.96.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $2.02 million for the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. Research analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current year.

Institutional Trading of Taysha Gene Therapies

Several institutional investors have recently modified their holdings of the company. Octagon Capital Advisors LP increased its holdings in Taysha Gene Therapies by 128.6% during the 4th quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company's stock valued at $18,078,000 after purchasing an additional 5,877,778 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of Taysha Gene Therapies during the fourth quarter worth $8,650,000. Bank of America Corp DE increased its stake in shares of Taysha Gene Therapies by 1,178.9% in the fourth quarter. Bank of America Corp DE now owns 1,710,303 shares of the company's stock valued at $2,959,000 after buying an additional 1,576,568 shares in the last quarter. Norges Bank bought a new position in shares of Taysha Gene Therapies in the fourth quarter valued at about $2,528,000. Finally, Avoro Capital Advisors LLC raised its holdings in shares of Taysha Gene Therapies by 7.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company's stock valued at $34,600,000 after buying an additional 1,349,999 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.